|1.||Lai, Ching-Lung: 11 articles (03/2014 - 09/2004)|
|2.||Brown, Nathaniel A: 10 articles (02/2009 - 09/2004)|
|3.||Ren, Hong: 7 articles (08/2015 - 05/2007)|
|4.||Naoumov, Nikolai V: 7 articles (08/2015 - 12/2007)|
|5.||Wang, Yuming: 7 articles (08/2015 - 12/2007)|
|6.||Bao, Weibin: 7 articles (08/2015 - 07/2009)|
|7.||Tang, Hong: 7 articles (02/2015 - 12/2011)|
|8.||Trylesinski, Aldo: 6 articles (08/2015 - 10/2012)|
|9.||Hou, Jinlin: 6 articles (04/2014 - 02/2008)|
|10.||Yuen, Man-Fung: 6 articles (03/2014 - 09/2004)|
|1.||Chronic Hepatitis B
12/14/2007 - "Telbivudine: a new treatment for chronic hepatitis B."
01/01/2014 - "An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B."
01/01/2015 - "[Clinical observation of telbivudine's antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy]."
01/01/2009 - "Safety and efficacy of telbivudine for the treatment of chronic hepatitis B."
04/01/2014 - "The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study."
05/01/2008 - "Hepatitis B goes globe: Telbivudine as a new treatment option."
04/01/2005 - "In in vitro studies and animal models, telbivudine has demonstrated potent and specific antiviral activity against hepatitis B. "
11/01/2015 - "Ultra-deep pyrosequencing (UDPS) was used to analyse the dynamics of quasispecies and resistant mutations during telbivudine (LDT) treatment of hepatitis B patients. "
01/01/2015 - "ALT CHANGES AND ADVERSE EVENTS OF TELBIVUDINE IN HEPATITIS-B PATIENTS-AN EXPERIENCE OF 11 PATIENTS."
11/01/2013 - "Treatment with telbivudine for fulminant hepatitis B."
02/01/2012 - "Telbivudine treatment has significantly improved the clinical outcome of chronic HBV infection. "
01/01/2012 - "Our meta-analysis provides preliminary evidence that telbivudine application in late pregnancy is effective in the interruption of intrauterine HBV infection, with no significant adverse effects or complications. "
02/01/2009 - "However, concerns about resistance with long-term use, along with inferior cost-effective analyses, have relegated telbivudine to a second-line agent in the management of chronic HBV infection."
01/01/2012 - "A few studies have evaluated the efficacy of telbivudine in preventing intrauterine HBV infection during late pregnancy. "
08/01/2009 - "To investigate the efficacy of telbivudine on intrauterine hepatitis B virus (HBV) infection during the last stage of pregnancy. "
07/01/2015 - "In conclusion, we showed that telbivudine administration in LT recipients for HBV cirrhosis was effective and it was associated with significant improvement in renal function, but this remains to be confirmed in larger well-designed studies."
04/01/2014 - "Data are limited for comparison of the long-term efficacy of telbivudine (LdT) between hepatitis B virus (HBV)-related compensated and decompensated cirrhosis. "
01/01/2014 - "In global trials of patients with compensated and decompensated cirrhosis, long-term telbivudine therapy was associated with a sustained improvement of renal function-particularly among patients with increased risk of renal impairment. "
04/01/2013 - "The results of this study support telbivudine as an effective therapy for patients with both compensated and decompensated HBV-related cirrhosis."
03/01/2015 - "We aimed to investigate whether telbivudine could prevent HBV-related fibrosis progression by their influence on CD4(+) T-cell response. "
|5.||Liver Cirrhosis (Hepatic Cirrhosis)
03/01/2015 - "Telbivudine might slow down HBV-related liver fibrosis progression by restoring CD4(+) T-cell responses against HBV."
04/01/2015 - "Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses."
04/01/2015 - "This study was aimed to evaluate the long-term effects of telbivudine (LdT) in the treatment of chronic hepatitis B (CHB) and HBV-related liver cirrhosis (LC) and to observe the changes of immunological responses during LdT treatment. "
03/01/2015 - "Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B."
01/01/2014 - "Increased eGFR with telbivudine treatment was also observed in patients at increased risk for renal impairment: patients with baseline eGFRs of 60-89 mL/min/1.73 m(2) (+17.2%), older than 50 years (+11.4%), and with liver fibrosis/cirrhosis (+7.2% for patients with Ishak fibrosis score at 5-6). "
|3.||Hepatitis B e Antigens
|6.||adefovir dipivoxil (Hepsera)
|8.||DNA (Deoxyribonucleic Acid)
|9.||tenofovir disoproxil (Viread)
|2.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)